SESSION TITLE: Pharmacotherapuetics
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: To assess the safety and tolerability of treatment with Rupatadine 10mg/day for 12 months in subjects with Asthma and Persistent Allergic Rhinitis (PAR), included in pulmonary rehabilitation program. Rupatadine is a novel antihistamine approved recently in Europe for the treatment of allergic rhinitis (AR) and chronic idiopathic urticaria in adults.